BRCA1 and breast cancer: These findings suggest that there likely exist additional signatures in the Sanger BRCA study that are missed in the PCAWG breast cancer study because of either the larger sample size or specific operative mutational processes (e.g., BRCA1 mutation carriers with signature SBS3) in Sanger BRCA study.